CN111132691A - 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗 - Google Patents

提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗 Download PDF

Info

Publication number
CN111132691A
CN111132691A CN201880051935.9A CN201880051935A CN111132691A CN 111132691 A CN111132691 A CN 111132691A CN 201880051935 A CN201880051935 A CN 201880051935A CN 111132691 A CN111132691 A CN 111132691A
Authority
CN
China
Prior art keywords
polysaccharide
conjugate
carrier protein
conjugates
serotypes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880051935.9A
Other languages
English (en)
Chinese (zh)
Inventor
S.V.卡普雷
A.K.达塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inventprise LLC
Original Assignee
Inventprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventprise LLC filed Critical Inventprise LLC
Priority to CN202410331847.1A priority Critical patent/CN118356485A/zh
Publication of CN111132691A publication Critical patent/CN111132691A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880051935.9A 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗 Pending CN111132691A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410331847.1A CN118356485A (zh) 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517905P 2017-06-10 2017-06-10
US62/517905 2017-06-10
PCT/US2018/036868 WO2018227177A1 (en) 2017-06-10 2018-06-11 Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410331847.1A Division CN118356485A (zh) 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Publications (1)

Publication Number Publication Date
CN111132691A true CN111132691A (zh) 2020-05-08

Family

ID=64562792

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880051935.9A Pending CN111132691A (zh) 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
CN202410331847.1A Pending CN118356485A (zh) 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410331847.1A Pending CN118356485A (zh) 2017-06-10 2018-06-11 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Country Status (12)

Country Link
US (1) US10688170B2 (https=)
EP (1) EP3634481A4 (https=)
JP (1) JP7132954B2 (https=)
KR (3) KR20240018698A (https=)
CN (2) CN111132691A (https=)
AU (1) AU2018280272C1 (https=)
BR (1) BR112019026192B1 (https=)
CA (1) CA3066911C (https=)
MX (2) MX2019014829A (https=)
MY (1) MY198400A (https=)
WO (1) WO2018227177A1 (https=)
ZA (1) ZA201908528B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022075575A (ja) * 2020-11-04 2022-05-18 ファイザー・インク 肺炎球菌ワクチンにおける使用のための免疫原性組成物
WO2023025003A1 (zh) * 2021-08-27 2023-03-02 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
CN117643624A (zh) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 一种双价多糖结合疫苗的制备方法及双价多糖结合疫苗

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
KR102225282B1 (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) * 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
KR20220017996A (ko) * 2019-06-05 2022-02-14 머크 샤프 앤드 돔 코포레이션 면역원성 혈청형 35b 폐렴구균 폴리사카라이드-단백질 접합체 및 그를 제조하기 위한 접합 방법
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
WO2021146681A1 (en) * 2020-01-17 2021-07-22 Inventprise, Llc Multivalent streptococcus vaccines
CN111643661A (zh) * 2020-06-08 2020-09-11 王竹林 新型免疫佐剂、化合物及其应用
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CN113173977B (zh) * 2021-05-12 2024-03-29 江苏坤力生物制药有限责任公司 一种双功能抗原、其制备方法及应用
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023176206A1 (ja) * 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
US20110195086A1 (en) * 2010-02-09 2011-08-11 Caulfield Michael J 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN103599529A (zh) * 2006-12-22 2014-02-26 惠氏公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN103656631A (zh) * 2012-09-24 2014-03-26 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
US20140105926A1 (en) * 2012-10-17 2014-04-17 Glaxosmithkline Biologicals S.A. Immunogenic composition

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
EP1532159A4 (en) 2002-06-20 2009-10-21 Univ Maryland Biotech Inst MALEIMIDES CLUSTERS ON SCAFFOLDING FOR PLURIVALENT PEPTIDE ASSEMBLIES
RU2340627C2 (ru) 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
EP1651262A2 (en) 2003-08-06 2006-05-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US20050118199A1 (en) 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
CN1993141A (zh) * 2004-06-04 2007-07-04 法麦克萨有限公司 诱导针对肺炎链球菌多糖的免疫应答
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP3311836A1 (en) 2005-04-08 2018-04-25 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2635208C (en) 2005-12-28 2018-03-20 The Uab Research Foundation Streptococcus pneumonia having a capsular polysaccharide repeating unit {>2)glucose 1(1>3) glucose 2 (1>3) rhamnose (1>3)ribitol (5>phosphate}
US8481054B2 (en) 2005-12-28 2013-07-09 The UAB Foundation Pneumococcal serotypes
WO2007106435A2 (en) 2006-03-10 2007-09-20 University Of California Cleavable vaccines compositions and methods of making and using the same
KR101711903B1 (ko) 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
BRPI0715396B8 (pt) 2006-08-07 2021-05-25 Harvard College método de produção de uma composição para vacina
CN101663327B (zh) 2007-03-23 2014-05-07 惠氏公司 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法
CA2692069C (en) 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2252326A4 (en) 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
BRPI0922981A8 (pt) 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
CN102686238A (zh) 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
PL2575870T3 (pl) 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
DK2885007T3 (en) 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
JP6502262B2 (ja) 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US20150079132A1 (en) 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
PL3096786T3 (pl) 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
US20150344530A1 (en) 2014-05-29 2015-12-03 Subhash V. Kapre Synthetic Peptides as Carriers for Conjugation with Polysaccharides
EA201700177A1 (ru) 2014-10-09 2017-07-31 Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком
US11147863B2 (en) 2015-06-23 2021-10-19 Biological E Limited Multivalent pneumococcal conjugate vaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CN103599529A (zh) * 2006-12-22 2014-02-26 惠氏公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20110195086A1 (en) * 2010-02-09 2011-08-11 Caulfield Michael J 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN103656631A (zh) * 2012-09-24 2014-03-26 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
US20140105926A1 (en) * 2012-10-17 2014-04-17 Glaxosmithkline Biologicals S.A. Immunogenic composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINGLONG WU ET AL.: ""Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm"" *
张哲 等: ""荚膜多糖及其疫苗研究进展"" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022075575A (ja) * 2020-11-04 2022-05-18 ファイザー・インク 肺炎球菌ワクチンにおける使用のための免疫原性組成物
WO2023025003A1 (zh) * 2021-08-27 2023-03-02 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
CN117643624A (zh) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 一种双价多糖结合疫苗的制备方法及双价多糖结合疫苗

Also Published As

Publication number Publication date
ZA201908528B (en) 2020-09-30
MX2019014829A (es) 2020-08-17
EP3634481A4 (en) 2021-07-21
JP7132954B2 (ja) 2022-09-07
MY198400A (en) 2023-08-28
EP3634481A1 (en) 2020-04-15
KR20240018698A (ko) 2024-02-13
KR20200014921A (ko) 2020-02-11
AU2018280272C1 (en) 2021-05-06
AU2018280272B2 (en) 2021-01-28
MX2023009362A (es) 2023-08-16
CA3066911A1 (en) 2018-12-13
CA3066911C (en) 2022-05-24
KR20240018697A (ko) 2024-02-13
AU2018280272A1 (en) 2020-01-30
BR112019026192A2 (pt) 2020-06-30
KR102634811B1 (ko) 2024-02-06
BR112019026192B1 (pt) 2022-05-10
US20180353591A1 (en) 2018-12-13
US10688170B2 (en) 2020-06-23
JP2020523323A (ja) 2020-08-06
CN118356485A (zh) 2024-07-19
WO2018227177A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
KR102634811B1 (ko) 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US12251438B2 (en) Immunogenic compositions of polysaccharide-protein pegylated compounds
CN103623405B (zh) 多糖-蛋白轭合物疫苗
CA2828787C (en) Conjugation of anitigen to carrier protein using triacetoxyborohydride
RU2634405C2 (ru) Иммуногенная композиция
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
CN109789198A (zh) 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
HU211210B (en) Method for preparing immunogenic oligosaccharide-protein-conjugates
AU2021207701A1 (en) Multivalent Streptococcus vaccines
US20250195640A1 (en) Immunogenic Compositions of Polysaccharide-Protein Pegylated Compounds
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
WO2026064646A1 (en) Immunogenic compositions of pegylated polysaccharide compounds
CN110652585B (zh) 多糖-蛋白缀合物免疫制剂及其制备与应用
Moingeon Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Delaware

Applicant after: Chuangju Co.

Address before: Washington State

Applicant before: Inventprise, LLC